CA-EASIC
eASIC Corp. (@easic ), a fabless semiconductor company that delivers a custom integrated circuit (IC) platform (eASIC Platform), and Comcores ApS , a leading provider of IP cores for wireless networks and an eZ-IP Alliance Partner , today announced immediate availability of a common public radio interface (CPRI) v6.1 switch reference design.
Ideally suited for manufacturers of next-generation LTE Advanced radio base stations and 5G networking equipment, it combines a Comcores CPRI Switch IP solution with eASIC’s Nextreme-3 silicon platform to offer a high-bandwidth solution for C-RAN (cloud or centralized radio access interface) fronthaul network applications.
Now, designers have all the essential ingredients in a single integrated platform for bridging between virtually any radio access that uses optical or microwave transport, and a centralized baseband pool that uses CPRI for communication. Equipped with the basic building blocks for a CPRI switch – an I/Q cross-connect, an Ethernet switch and CPRI v6.1 controller IP – packaged as a complete reference design, customers can dramatically shorten design cycles, while cutting costs and mitigating the risks associated with designing “from scratch.”
“Together with Comcores, we’re delivering an ideal platform for rapid and cost effective deployment of fronthaul technology,” said Jasbinder Bhoot, vice president of worldwide marketing at eASIC. “With today’s news, designers now have an efficient, no-compromise solution for jumpstarting LTE-Advanced and 5G wireless communications system designs to address stringent cost, performance and time-to-market requirements for next-generation C-RAN fronthaul applications.”
“We’re pleased to extend our collaboration with eASIC with delivery of a CPRI v6.1 switch reference design,” said Thomas Noergaard, CEO of Comcores. “Our optimized core is a perfect match for eASIC silicon. It fully exploits the high performance 12.5 Gbps serial transceivers to achieve multiple hundreds of gigabit of serial throughput depending on the switch configuration. And, it can be dynamically configured to handle wireless multi-mode radio systems, addressing the deterministic latency and high-performance throughputs required by LTE Advanced radio base stations. Altogether, this puts a concrete solution in the hands of customers for making the C-RAN vision a reality for next-generation fronthaul design and deployment.”
A key requirement for fulfilling the industry’s vision for the C-RAN architecture is the availability of a high throughput, flexible fronthaul connection between the new network architecture of centralized baseband controllers and remote standalone radio heads at cell sites at line rates of up to 12.2 Gbps enabled in the CPRI v6.1 specification.
Among the technical features of the new reference design from eASIC and Comcores are:
- Up to 52 ports non-blocking, user-plane switch using an eASIC N3XT1300_FC1517 device
- Switching at antenna carrier (AxC) level
- Low system clock rate of 245.76 MHz to optimize performance and power
- Dynamically supports 1:1 connectivity, broadcast or multicast operation
- Support for optional Ethernet switch for Control and Management
- Support for optional ORI compliant compression IP
About Comcores
Comcores is a market leader in the development of state-of-the-art IP-cores for wireless front-haul and C-RAN. The company provides modular IP blocks and components for connectivity and radio functionality in existing and next generation mobile infrastructure networks. Comcores offers leading IP cores solutions, expertise in research and development as well as custom design solutions.
For more information please visit www.comcores.com .
About eASIC
eASIC is a semiconductor company offering a differentiated solution that enables us to rapidly and cost-effectively deliver custom ICs, creating value for our customers’ hardware and software systems. Our eASIC solution consists of our eASIC platform which incorporates a versatile, pre-defined and reusable base array and customizable single-mask layer, our ASICs, delivered using either our easicopy or standard ASIC methodologies, and our proprietary design tools.
We believe this innovative technology allows eASIC to offer the optimal combination of fast time-to-market, high performance, low power consumption, low development cost and low unit cost for our customers. eASIC Corporation is headquartered in Santa Clara, California. Investors include Khosla Ventures, Crescendo Ventures, Seagate Technology, Kleiner Perkins Caufield and Byers (KPCB) and Evergreen Partners.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150616005720/en/
Contact:
Editorial Contacts:
eASIC Corporation
Lisa Washington,
408-855-9200
lwashington@easic.com
or
Comcores
ApS
Thomas Noergaard, +45 70707624
Thomas.Noergaard@comcores.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum